The global liver cirrhosis treatment market accounted for USD 7.17 billion in 2023 and is expected to reach at USD 22.43 billion by 2034 with a CAGR of 10.93% during the forecast period 2024-2034. The market will grow as a result of factors such as the increasing prevalence of liver cirrhosis, technological advancements in medicine, increased awareness and screening initiatives, rising demand for liver transplants, and smart alliances and coordination.
Numerous conditions, including alcohol misuse, viral hepatitis (including hepatitis B and C), non-alcoholic fatty liver disease (NAFLD), and autoimmune liver illnesses, can induce liver cirrhosis, which is a major global health burden. The demand for therapeutic alternatives is fueled by the rising frequency and prevalence of these underlying diseases, which also increase the prevalence of liver cirrhosis. For instance, in May 2023, Gilead Sciences, Inc. reported favorable outcomes from a Phase 3 trial assessing filgotinib as a possible treatment for cirrhosis caused by non-alcoholic steatohepatitis (NASH).
By treatment type, the antiviral drugs segment accounted for the highest revenue-grossing segment in the global liver cirrhosis treatment market in 2023 owing to the high prevalence of viral hepatitis, particularly hepatitis C, a major cause of cirrhosis. For instance, in April 2024, AbbVie Inc. received FDA clearance for Skyrizi (risankizumab-rzaa), a medication used to treat individuals with moderate to severe active Crohn's disease, which can occasionally result in cirrhosis. Additionally, the target therapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the development of new, more specific drugs that target the underlying mechanisms of cirrhosis progression.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global liver cirrhosis treatment market in 2023 owing to the complex nature of liver cirrhosis treatment, which often requires hospitalization for procedures or close monitoring. For instance, in February 2024, the Bristol-Myers Squibb Company presented data at a medical conference showcasing the potential of Yervoy (ipilimumab) in conjunction with Opdivo (nivolumab) for the treatment of hepatocellular carcinoma (HCC), a kind of liver cancer that can arise from cirrhosis. Additionally, the ambulatory surgical centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of minimally invasive procedures for liver cirrhosis treatment.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-developed healthcare infrastructure, high prevalence of liver diseases, and strong government support for research and development. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising prevalence of hepatitis B, increasing disposable income, and growing awareness of liver diseases. For instance, in December 2023, Merck & Co., Inc. announced that it was partnering with a biotechnology company to create new treatments that specifically target pathways linked to liver fibrosis, a defining feature of the evolution of cirrhosis.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Numerous conditions, including alcohol misuse, viral hepatitis (including hepatitis B and C), non-alcoholic fatty liver disease (NAFLD), and autoimmune liver illnesses, can induce liver cirrhosis, which is a major global health burden. The demand for therapeutic alternatives is fueled by the rising frequency and prevalence of these underlying diseases, which also increase the prevalence of liver cirrhosis. For instance, in May 2023, Gilead Sciences, Inc. reported favorable outcomes from a Phase 3 trial assessing filgotinib as a possible treatment for cirrhosis caused by non-alcoholic steatohepatitis (NASH).
By treatment type, the antiviral drugs segment accounted for the highest revenue-grossing segment in the global liver cirrhosis treatment market in 2023 owing to the high prevalence of viral hepatitis, particularly hepatitis C, a major cause of cirrhosis. For instance, in April 2024, AbbVie Inc. received FDA clearance for Skyrizi (risankizumab-rzaa), a medication used to treat individuals with moderate to severe active Crohn's disease, which can occasionally result in cirrhosis. Additionally, the target therapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the development of new, more specific drugs that target the underlying mechanisms of cirrhosis progression.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global liver cirrhosis treatment market in 2023 owing to the complex nature of liver cirrhosis treatment, which often requires hospitalization for procedures or close monitoring. For instance, in February 2024, the Bristol-Myers Squibb Company presented data at a medical conference showcasing the potential of Yervoy (ipilimumab) in conjunction with Opdivo (nivolumab) for the treatment of hepatocellular carcinoma (HCC), a kind of liver cancer that can arise from cirrhosis. Additionally, the ambulatory surgical centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of minimally invasive procedures for liver cirrhosis treatment.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-developed healthcare infrastructure, high prevalence of liver diseases, and strong government support for research and development. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising prevalence of hepatitis B, increasing disposable income, and growing awareness of liver diseases. For instance, in December 2023, Merck & Co., Inc. announced that it was partnering with a biotechnology company to create new treatments that specifically target pathways linked to liver fibrosis, a defining feature of the evolution of cirrhosis.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Treatment Type, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement
Segmentation: Liver Cirrhosis Treatment Market Report 2023 - 2034
Liver Cirrhosis Treatment Market Analysis & Forecast by Treatment Type 2023 - 2034 (Revenue USD Bn)
- Antiviral Drugs
- Immunosuppressants
- Vaccines
- Immunoglobulins
- Target Therapy
- Others
Liver Cirrhosis Treatment Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
Liver Cirrhosis Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Liver Cirrhosis Treatment Market: Treatment Type Estimates & Trend Analysis
8. Liver Cirrhosis Treatment Market: End-User Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Liver Cirrhosis Treatment Market
11. Europe Global Liver Cirrhosis Treatment Market
12. Asia Pacific Global Liver Cirrhosis Treatment Market
13. Latin America Global Liver Cirrhosis Treatment Market
14. MEA Global Liver Cirrhosis Treatment Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Gilead Sciences Inc.. AbbVie Inc.
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc
- Johnson & Johnson (Janssen Pharmaceuticals)
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Roche Holding AG
- Allergan plc
- Intercept Pharmaceuticals Inc.
- Shionogi & Co. Ltd.
- AstraZeneca plc
- Lilly
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | October 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 7.17 Billion |
| Forecasted Market Value ( USD | $ 22.43 Billion |
| Compound Annual Growth Rate | 10.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 14 |
